Notes
2017 US dollars
Reference
Zimmerman M, et al. Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease. Value in Health : 25 Oct 2018. Available from: URL: https://doi.org/10.1016/j.jval.2018.09.2841
Rights and permissions
About this article
Cite this article
Voretigene neparvovec unlikely to be cost effective in USA. PharmacoEcon Outcomes News 816, 34 (2018). https://doi.org/10.1007/s40274-018-5454-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5454-5